Verition Fund Management
BDTX icon

Verition Fund Management’s Black Diamond Therapeutics BDTX Stock Holding History

Verition Fund Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-125,250
Closed -$584K – 3190
2024
Q2 		$584K Sell
125,250
-203,656
-62% -$1.09M ﹤0.01% 1973
2024
Q1 		$1.67M Sell
328,906
-1,225,723
-79% -$4.94M 0.01% 1316
2023
Q4 		$4.37M Sell
1,554,629
-181,040
-10% -$425K 0.03% 494
2023
Q3 		$4.98M Buy
1,735,669
+1,284,978
+285% +$4.73M 0.06% 433
2023
Q2 		$2.28M Buy
450,691
+106,384
+31% +$217K 0.03% 628
2023
Q1 		$651K Buy
+344,307
New +$791K 0.01% 1110

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

Verition Fund Management's BDTX Position: Q3 2024 in Review

Verition Fund Management sold out of Black Diamond Therapeutics (BDTX) in Q3 2024, closing a stake of 125,250 shares — an estimated $584K sold.

Verition Fund Management first reported a position in BDTX in Q1 2023 and held it in 6 quarters. The position peaked at $4.98M in Q3 2023. 96 funds tracked by Wall St. Rank hold BDTX as of Q3 2024.

  • Verition Fund Management reported no remaining Black Diamond Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Verition Fund Management sold 125,250 Black Diamond Therapeutics shares in Q3 2024, an estimated $584K.
  • Verition Fund Management first reported a position in Black Diamond Therapeutics in Q1 2023 and held it in 6 quarters.
  • Verition Fund Management's Black Diamond Therapeutics position peaked at $4.98M in Q3 2023.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2024.

Based on Verition Fund Management's 13F filing for Q3 2024, filed 14 Nov 2024.